Table 4.

HRs (95% CIs) for Incident CHD by Lp-PLA2 Quartile^*

	Lp-PLA2 Quartiles
	2nd Quartile	3rd Quartile	4th Quartile
	(409.9–488.4 ng/ml)	(488.5–625.2 ng/ml)	(> 625.2 ng/ml)
Model 1	1.66 (1.09–2.54) [269]	1.80 (1.19–2.72) [270]	1.89 (1.26–2.86) [269]
Model 2	1.54 (1.01–2.37) [269]	1.71 (1.12–2.61) [270]	1.61 (1.03–2.51) [269]
Model 3	1.59 (1.04–2.44) [269]	1.83 (1.21–2.77) [270]	1.81 (1.20–2.73) [269]
Model 4	1.41 (0.87–2.26) [211]	1.93 (1.22–3.07) [198]	1.75 (1.10–2.77) [199]
Model 5	1.43 (0.89–2.31) [211]	1.96 (1.23–3.10) [198]	1.75 (1.10–2.78) [199]

^*Lowest quartile (<409.9 ng/ml) is reference. The number in brackets is the n for each quartile. Quartile cutpoints were calculated based on the sample of 1,077. The n for Q1 is [269] for Models 1, 2, and 3 and [209] for Models 4 and 5. Model 1 (n = 1,077): adjusted for age and gender; Model 2 (n = 1,077): adjusted for age, gender, fasting plasma glucose, systolic blood pressure, hypertension, diabetes, low-density lipoprotein, lnhigh-density lipoprotein, and lntriglycerides; Model 3 (n = 1,077): adjusted for age, gender, fasting plasma glucose, systolic blood pressure; Model 4 (n = 815): Model 3, but includes only those subjects who had C-reactive protein measured (C-reactive protein not in the model); Model 5 (n = 815): Model 4 + C-reactive protein.

CHD = coronary heart disease; CI = confidence interval; HR = hazard ratio; ln = natural logarithm; Lp-PLA2 = lipoprotein-associated phospholipase A2.